<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Med Sci Monit</journal-id><journal-id journal-id-type="iso-abbrev">Med. Sci. Monit</journal-id><journal-id journal-id-type="publisher-id">Medical Science Monitor</journal-id><journal-title-group><journal-title>Medical Science Monitor : International Medical Journal of Experimental and Clinical Research</journal-title></journal-title-group><issn pub-type="ppub">1234-1010</issn><issn pub-type="epub">1643-3750</issn><publisher><publisher-name>International Scientific Literature, Inc.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24019010</article-id><article-id pub-id-type="pmc">3775615</article-id><article-id pub-id-type="doi">10.12659/MSM.889443</article-id><article-id pub-id-type="publisher-id">889443</article-id><article-categories><subj-group subj-group-type="heading"><subject>Drug Controlled Studies</subject></subj-group></article-categories><title-group><article-title>Combination lamivudine and adefovir <italic>versus</italic> entecavir for the treatment of naïve chronic hepatitis B patients: A pilot study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Du</surname><given-names>Qing-Wei</given-names></name><xref ref-type="author-notes" rid="fn1-medscimonit-19-751">A</xref><xref ref-type="author-notes" rid="fn2-medscimonit-19-751">B</xref><xref ref-type="author-notes" rid="fn3-medscimonit-19-751">C</xref><xref ref-type="author-notes" rid="fn4-medscimonit-19-751">D</xref></contrib><contrib contrib-type="author"><name><surname>Ding</surname><given-names>Ji-Guang</given-names></name><xref ref-type="author-notes" rid="fn1-medscimonit-19-751">A</xref><xref ref-type="author-notes" rid="fn2-medscimonit-19-751">B</xref><xref ref-type="author-notes" rid="fn3-medscimonit-19-751">C</xref><xref ref-type="author-notes" rid="fn4-medscimonit-19-751">D</xref><xref ref-type="author-notes" rid="fn5-medscimonit-19-751">E</xref><xref ref-type="author-notes" rid="fn6-medscimonit-19-751">F</xref></contrib><contrib contrib-type="author"><name><surname>Sun</surname><given-names>Qing-Feng</given-names></name><xref ref-type="author-notes" rid="fn1-medscimonit-19-751">A</xref><xref ref-type="author-notes" rid="fn2-medscimonit-19-751">B</xref><xref ref-type="author-notes" rid="fn3-medscimonit-19-751">C</xref><xref ref-type="author-notes" rid="fn4-medscimonit-19-751">D</xref><xref ref-type="author-notes" rid="fn5-medscimonit-19-751">E</xref><xref ref-type="author-notes" rid="fn6-medscimonit-19-751">F</xref><xref ref-type="author-notes" rid="fn7-medscimonit-19-751">G</xref><xref ref-type="corresp" rid="c1-medscimonit-19-751"></xref></contrib><contrib contrib-type="author"><name><surname>Hong</surname><given-names>Liang</given-names></name><xref ref-type="author-notes" rid="fn1-medscimonit-19-751">A</xref><xref ref-type="author-notes" rid="fn3-medscimonit-19-751">C</xref><xref ref-type="author-notes" rid="fn4-medscimonit-19-751">D</xref></contrib><contrib contrib-type="author"><name><surname>Cai</surname><given-names>Fu-Jing</given-names></name><xref ref-type="author-notes" rid="fn2-medscimonit-19-751">B</xref><xref ref-type="author-notes" rid="fn3-medscimonit-19-751">C</xref></contrib><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Qing-Qing</given-names></name><xref ref-type="author-notes" rid="fn1-medscimonit-19-751">A</xref><xref ref-type="author-notes" rid="fn2-medscimonit-19-751">B</xref><xref ref-type="author-notes" rid="fn4-medscimonit-19-751">D</xref><xref ref-type="author-notes" rid="fn5-medscimonit-19-751">E</xref></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Yang-He</given-names></name><xref ref-type="author-notes" rid="fn2-medscimonit-19-751">B</xref><xref ref-type="author-notes" rid="fn3-medscimonit-19-751">C</xref><xref ref-type="author-notes" rid="fn4-medscimonit-19-751">D</xref></contrib><contrib contrib-type="author"><name><surname>Fu</surname><given-names>Rong-Quan</given-names></name><xref ref-type="author-notes" rid="fn2-medscimonit-19-751">B</xref><xref ref-type="author-notes" rid="fn3-medscimonit-19-751">C</xref></contrib><aff id="af1-medscimonit-19-751">Department of Infectious Diseases, Third Affiliated Hospital to Wenzhou Medical College, Ruian, Zhejiang, P.R. China</aff></contrib-group><author-notes><corresp id="c1-medscimonit-19-751">Corresponding Author: Qing-Feng Sun, e-mail: <email>sunxue0806@126.com</email></corresp><fn id="fn1-medscimonit-19-751"><label>A</label><p>Study Design</p></fn><fn id="fn2-medscimonit-19-751"><label>B</label><p>Data Collection</p></fn><fn id="fn3-medscimonit-19-751"><label>C</label><p>Statistical Analysis</p></fn><fn id="fn4-medscimonit-19-751"><label>D</label><p>Data Interpretation</p></fn><fn id="fn5-medscimonit-19-751"><label>E</label><p>Manuscript Preparation</p></fn><fn id="fn6-medscimonit-19-751"><label>F</label><p>Literature Search</p></fn><fn id="fn7-medscimonit-19-751"><label>G</label><p>Funds Collection</p></fn></author-notes><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>09</day><month>9</month><year>2013</year></pub-date><volume>19</volume><fpage>751</fpage><lpage>756</lpage><history><date date-type="received"><day>07</day><month>6</month><year>2013</year></date><date date-type="accepted"><day>16</day><month>7</month><year>2013</year></date></history><permissions><copyright-statement>© Med Sci Monit, 2013</copyright-statement><copyright-year>2013</copyright-year><license><license-p>This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License</license-p></license></permissions><abstract><sec><title><offsets xml_i="5860" xml_f="5870" txt_i="11" txt_f="21">Background</offsets></title><p><offsets xml_i="5881" xml_f="5990" txt_i="22" txt_f="131">The aim of this study was to compare the effect of combination lamivudine (LAM) and adefovir dipivoxil (ADV) </offsets><italic><offsets xml_i="5998" xml_f="6004" txt_i="131" txt_f="137">versus</offsets></italic><offsets xml_i="6013" xml_f="6102" txt_i="137" txt_f="226"> entecavir (ETV) monotherapy for naïve HBeAg-positive chronic hepatitis B (CHB) patients.</offsets></p></sec><sec><title><offsets xml_i="6124" xml_f="6140" txt_i="228" txt_f="244">Material/Methods</offsets></title><p><offsets xml_i="6151" xml_f="6773" txt_i="245" txt_f="867">Fifty enrolled patients with CHB were evenly divided into 2 groups: a group treated with of lamivudine (LAM) (100 mg/day) plus adefovir (ADV) (10 mg/day) combination, and a group treated with entecavir (ETV) (0.5 mg/day). Serum levels of ALT, AST, creatinine, bilirubin, HBsAg, HBeAg and HBV viral load, and genotypic resistance were analyzed at 0, 12, 24, 52, and 104 weeks. HBV DNA levels were determined by real-time PCR and HBsAg and HBeAg by chemiluminescence. Serum levels of ALT, AST, creatinine, and bilirubin were measured by an automatic biochemical analyzer. Data analysis was performed with SPSS 12.0 software.</offsets></p></sec><sec><title><offsets xml_i="6795" xml_f="6802" txt_i="869" txt_f="876">Results</offsets></title><p><offsets xml_i="6813" xml_f="7344" txt_i="877" txt_f="1405">There were no significant differences in the virological response (VR) rates between LAM+ADV and ETV cohorts at 24, 52, and 104 weeks (P&gt;0.05). The HBeAg seroconversion rates were 28% and 20%, and the biochemical response (BR) rates were 88% and 84% at week 104 in the LAM+ADV and ETV groups, respectively. The rates of undetectable HBV DNA, HBeAg seroconversion, and ALT normalization rates were similar in both cohorts. No virological breakthrough or serious adverse effects were noted for any patient during the study period.</offsets></p></sec><sec><title><offsets xml_i="7366" xml_f="7377" txt_i="1407" txt_f="1418">Conclusions</offsets></title><p><offsets xml_i="7388" xml_f="7586" txt_i="1419" txt_f="1617">Both LAM + ADV combination therapy and ETV monotherapy were effective and safe in the treatment of naïve HBeAg-positive CHB patients. However, further studies are needed to obtain long-term results.</offsets></p></sec></abstract><kwd-group><kwd>chronic hepatitis B</kwd><kwd>HBeAg-positive</kwd><kwd>lamivudine</kwd><kwd>adefovir dipivoxil</kwd><kwd>entecavir</kwd></kwd-group></article-meta></front><body><sec><title><offsets xml_i="7796" xml_f="7806" txt_i="1626" txt_f="1636">Background</offsets></title><p><offsets xml_i="7817" xml_f="8002" txt_i="1637" txt_f="1822">Hepatitis B virus (HBV) is a major health problem worldwide, and is the most serious type of viral hepatitis. It can cause chronic liver disease and lead to liver cirrhosis and cancer [</offsets><xref ref-type="bibr" rid="b1-medscimonit-19-751"><offsets xml_i="8052" xml_f="8053" txt_i="1822" txt_f="1823">1</offsets></xref><offsets xml_i="8060" xml_f="8181" txt_i="1823" txt_f="1944">]. HBeAg-positive chronic hepatitis B (CHB) patients usually have high levels of HBV DNA, and high risk of liver cancer [</offsets><xref ref-type="bibr" rid="b2-medscimonit-19-751"><offsets xml_i="8231" xml_f="8232" txt_i="1944" txt_f="1945">2</offsets></xref><offsets xml_i="8239" xml_f="8342" txt_i="1945" txt_f="2048">]. Therefore, effective antiviral therapy is necessary in the treatment of HBeAg-positive CHB patients.</offsets></p><p><offsets xml_i="8349" xml_f="8904" txt_i="2049" txt_f="2604">Current nucleos(t)ide analogues for CHB patients in China include lamivudine, adefovir dipivoxil, entecavir, and telbivudine. Patients who need long-term treatment usually need initial therapy involving either a combination of nucleoside/nucleotide analogs or monotherapy with higher efficiency and lower resistance, such as entecavir or tenofovir disoproxil (tenofovir disoproxil is not approved for HBV use in China). However, the guidelines did not advocate the initial use of combination therapy in 2008 at the time of initiation of the current study.</offsets></p><p><offsets xml_i="8911" xml_f="8977" txt_i="2605" txt_f="2671">It is well established that the use of LAM is safe and effective [</offsets><xref ref-type="bibr" rid="b3-medscimonit-19-751"><offsets xml_i="9027" xml_f="9028" txt_i="2671" txt_f="2672">3</offsets></xref><offsets xml_i="9035" xml_f="9343" txt_i="2672" txt_f="2980">]. Nevertheless, long-term use of lamivudine unfortunately leads to emergence of resistance to hepatitis B virus (YMDD) mutants. Despite this, lamivudine is still used widely because it is well tolerated. ADV has been strongly considered as a rescue therapeutic agent for the treatment of resistant mutants [</offsets><xref ref-type="bibr" rid="b4-medscimonit-19-751"><offsets xml_i="9393" xml_f="9394" txt_i="2980" txt_f="2981">4</offsets></xref><offsets xml_i="9401" xml_f="9402" txt_i="2981" txt_f="2982">,</offsets><xref ref-type="bibr" rid="b5-medscimonit-19-751"><offsets xml_i="9452" xml_f="9453" txt_i="2982" txt_f="2983">5</offsets></xref><offsets xml_i="9460" xml_f="9576" txt_i="2983" txt_f="3099">]. The clinical efficacy of entecavir has been studied in several randomized, double-blind, and multicenter trials [</offsets><xref ref-type="bibr" rid="b6-medscimonit-19-751"><offsets xml_i="9626" xml_f="9627" txt_i="3099" txt_f="3100">6</offsets></xref><offsets xml_i="9634" xml_f="9721" txt_i="3100" txt_f="3187">]. Oral entecavir was found to be an effective and generally well tolerated treatment [</offsets><xref ref-type="bibr" rid="b7-medscimonit-19-751"><offsets xml_i="9771" xml_f="9772" txt_i="3187" txt_f="3188">7</offsets></xref><offsets xml_i="9779" xml_f="9781" txt_i="3188" txt_f="3190">].</offsets></p><p><offsets xml_i="9788" xml_f="9933" txt_i="3191" txt_f="3336">Previous studies have shown that combination therapy can reduce the viral resistance anti-HBV agents, permitting their use in long-term therapy [</offsets><xref ref-type="bibr" rid="b8-medscimonit-19-751"><offsets xml_i="9983" xml_f="9984" txt_i="3336" txt_f="3337">8</offsets></xref><offsets xml_i="9991" xml_f="10090" txt_i="3337" txt_f="3436">]. Adding ADV to LAM enhanced the virological and biochemical responses in LAM-resistant patients [</offsets><xref ref-type="bibr" rid="b9-medscimonit-19-751"><offsets xml_i="10140" xml_f="10141" txt_i="3436" txt_f="3437">9</offsets></xref><offsets xml_i="10148" xml_f="10247" txt_i="3437" txt_f="3536">], and adding ADV to LAM increased efficacy compared to ADV monotherapy in LAM-resistant patients [</offsets><xref ref-type="bibr" rid="b10-medscimonit-19-751"><offsets xml_i="10298" xml_f="10300" txt_i="3536" txt_f="3538">10</offsets></xref><offsets xml_i="10307" xml_f="10308" txt_i="3538" txt_f="3539">,</offsets><xref ref-type="bibr" rid="b11-medscimonit-19-751"><offsets xml_i="10359" xml_f="10361" txt_i="3539" txt_f="3541">11</offsets></xref><offsets xml_i="10368" xml_f="10410" txt_i="3541" txt_f="3583">]. Thus, LAM and ADV were considered as a </offsets><italic><offsets xml_i="10418" xml_f="10425" txt_i="3583" txt_f="3590">de novo</offsets></italic><offsets xml_i="10434" xml_f="10653" txt_i="3590" txt_f="3809"> combination treatment, and entecavir (ETV) was recommended as first line monotherapy for long-term treatment of naïve CHB patients. Additionally, the cost of LAM combined with ADV is less than ETV monotherapy in China.</offsets></p><p><offsets xml_i="10660" xml_f="10766" txt_i="3810" txt_f="3916">Both LAM +ADV combination therapy and ETV monotherapy are effective in naïve HBeAg-negative CHB patients [</offsets><xref ref-type="bibr" rid="b12-medscimonit-19-751"><offsets xml_i="10817" xml_f="10819" txt_i="3916" txt_f="3918">12</offsets></xref><offsets xml_i="10826" xml_f="11082" txt_i="3918" txt_f="4174">]. However, it is unclear whether the combination of LAM and ADV is effective in HBeAg positive patients. The aim of this study was to evaluate and compare the effect of LAM plus ADV or ETV monotherapy in the treatment of naïve HBeAg-positive CHB patients.</offsets></p></sec><sec sec-type="materials|methods"><title><offsets xml_i="11133" xml_f="11153" txt_i="4176" txt_f="4196">Material and Methods</offsets></title><p><offsets xml_i="11164" xml_f="11631" txt_i="4197" txt_f="4664">Informed consent was obtained from each patient, and ethics approval for this study was given by the Ethics Committee at the Third Affiliated Hospital of Wenzhou Medical College. There were 50 patients enrolled in this study. All patients were outpatients between November 2008 and June 2010. HBsAg was present in all the patients for at least 6 months prior to enrollment. All of the patients were both HBV DNA and HBeAg positive. The minimum level of HBV DNA was 10</offsets><sup><offsets xml_i="11636" xml_f="11637" txt_i="4664" txt_f="4665">4</offsets></sup><offsets xml_i="11643" xml_f="12402" txt_i="4665" txt_f="5424"> copies/ml. Patients in whom the liver enzymes were elevated more than twice the ULN, but not more than 10 times, were enrolled without liver biopsy. Patients whose liver enzymes were elevated less than twice the ULN had liver biopsies to analyze the relation of hepatic grades of inflammation and stages of fibrosis. Patients with inflammation grade ≥2 or fibrosis stage ≥2 were enrolled in this study. Patients co-infected with hepatitis A virus, hepatitis C virus, hepatitis D virus, hepatitis E virus, or human immunodeficiency virus (HIV) or with alcoholic cirrhosis, autoimmune hepatitis, organ transplantation, HCC, or other severe diseases such as renal insufficiency were excluded from this study. Moreover, children and pregnant women were excluded.</offsets></p><p><offsets xml_i="12409" xml_f="12503" txt_i="5425" txt_f="5519">This study aimed to evaluate and compare the efficacy of combination lamivudine plus adefovir </offsets><italic><offsets xml_i="12511" xml_f="12517" txt_i="5519" txt_f="5525">versus</offsets></italic><offsets xml_i="12526" xml_f="12954" txt_i="5525" txt_f="5953"> entecavir monotherapy. Patients in the combination therapy group received LAM 100 mg and ADV 10 mg per day and the monotherapy group received ETV 0.5 mg per day. Clinical data were collected at baseline and every 3 months after retreatment. The primary efficacy outcomes were ALT normalization, reduction in HBV DNA, and seroconversion of HBeAg. We contacted the patients by phone every 3 months to increase patient compliance.</offsets></p><sec><title><offsets xml_i="12970" xml_f="12993" txt_i="5954" txt_f="5977">Serum assay methodology</offsets></title><p><offsets xml_i="13004" xml_f="13538" txt_i="5978" txt_f="6512">Serum levels of ALT, AST, and bilirubin were measured at baseline and again at weeks 12, 24, 52, and 104 of the treatment using an Automatic Biochemistry analyzer (Olympus AU5431, Olympus Corporation, Tokyo, Japan) according to the manufacturer’s instructions. The status of HBsAg, HBeAg, and antibody to HBeAg (anti-HBe) were measured by a microparticle enzyme-linked immunosorbent assay as recommended by the manufacturer (ELISA, Abbott Laboratories, United States) at each time point (week 0, 12, 24, 52, and 104) during treatment.</offsets></p></sec><sec><title><offsets xml_i="13560" xml_f="13580" txt_i="6514" txt_f="6534">HBV DNA quantitation</offsets></title><p><offsets xml_i="13591" xml_f="14012" txt_i="6535" txt_f="6956">From cell lysates, DNA was extracted and amplified by real-time PCR. The amplification was performed according to the protocol provided by Daan Gene Co., Shenzhen, China, the manufacturer of the primers, using an ABI7500 cycler: 93°C for 2 min, 93°C for 45 sec, followed b 55°C 60 sec 10 cycles, and 93°C for 30 sec followed by 55°C 45 sec 30 cycles. Values under or over the detection range were recorded as 2.7 or 9 log</offsets><sub><offsets xml_i="14017" xml_f="14019" txt_i="6956" txt_f="6958">10</offsets></sub><offsets xml_i="14025" xml_f="14050" txt_i="6958" txt_f="6983"> copies/ml, respectively.</offsets></p></sec><sec><title><offsets xml_i="14072" xml_f="14083" txt_i="6985" txt_f="6996">Definitions</offsets></title><p><offsets xml_i="14094" xml_f="14543" txt_i="6997" txt_f="7443">The biochemical response (BR) was defined as normalization of ALT levels. Virological response was defined as a decrease in serum HBV DNA to undetectable levels by PCR assays (&lt;500 copies/mL). HBeAg response was defined as seroconversion of HBeAg. Virological breakthrough was defined as an increase in serum HBV DNA by 1log10 (10-fold) above nadir, or to detectable level (≥500 copies/mL) after achieving virological response during retreatment.</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="14584" xml_f="14604" txt_i="7445" txt_f="7465">Statistical analysis</offsets></title><p><offsets xml_i="14615" xml_f="14680" txt_i="7466" txt_f="7531">Comparisons between groups of variables were performed using the </offsets><italic><offsets xml_i="14688" xml_f="14689" txt_i="7531" txt_f="7532">t</offsets></italic><offsets xml_i="14698" xml_f="15017" txt_i="7532" txt_f="7848">-test, and a chi-square test or Fisher’s exact test. Repeated measure ANOVA was used to analyze the differences at various time points. All tests were 2-sided and used a significance level of P&lt;0.05. Data handling and analysis were performed with SPSS software for Windows, version 13.0 (SPSS Inc, Chicago, IL, USA).</offsets></p></sec></sec><sec sec-type="results"><title><offsets xml_i="15064" xml_f="15071" txt_i="7851" txt_f="7858">Results</offsets></title><sec sec-type="intro|methods|subjects"><title><offsets xml_i="15125" xml_f="15162" txt_i="7859" txt_f="7896">Characteristics of the study patients</offsets></title><p><offsets xml_i="15173" xml_f="15189" txt_i="7897" txt_f="7913">As described in </offsets><xref ref-type="table" rid="t1-medscimonit-19-751"><offsets xml_i="15240" xml_f="15247" txt_i="7913" txt_f="7920">Table 1</offsets></xref><offsets xml_i="15254" xml_f="15583" txt_i="7920" txt_f="8249">, 50 patients were included in either the LAM + ADV combination group (n=25) or the ETV monotherapy group (n=25). In the combination group, 20 patients were male (80%), with a mean age of 33.4±9.8 years (range, 18–52 years). In the monotherapy group, there were 19 males (76%) and mean age was 30.8±7.1 years (range 18–45 years).</offsets></p><p><offsets xml_i="15590" xml_f="15668" txt_i="8250" txt_f="8328">The median level of HBV DNA in the LAM + ADV group was 6.02±1.6 (range 8.27×10</offsets><sup><offsets xml_i="15673" xml_f="15674" txt_i="8328" txt_f="8329">4</offsets></sup><offsets xml_i="15680" xml_f="15688" txt_i="8329" txt_f="8337">–2.90×10</offsets><sup><offsets xml_i="15693" xml_f="15694" txt_i="8337" txt_f="8338">8</offsets></sup><offsets xml_i="15700" xml_f="15856" txt_i="8338" txt_f="8494"> copies/mL). The median level of ALT was 173 IU/L (range 28–456 IU/L). In the ETV monotherapy group, the median level of HBV DNA was 5.94±1.2 (range 1.06×10</offsets><sup><offsets xml_i="15861" xml_f="15862" txt_i="8494" txt_f="8495">4</offsets></sup><offsets xml_i="15868" xml_f="15876" txt_i="8495" txt_f="8503">–3.51×10</offsets><sup><offsets xml_i="15881" xml_f="15882" txt_i="8503" txt_f="8504">8</offsets></sup><offsets xml_i="15888" xml_f="16038" txt_i="8504" txt_f="8654"> copies/mL) and the mean ALT was 156 IU/L (range 64–531 IU/L). There were no significant differences in baseline characteristics between the 2 groups.</offsets></p></sec><sec><title><offsets xml_i="16060" xml_f="16080" txt_i="8656" txt_f="8676">Virological response</offsets></title><p><offsets xml_i="16091" xml_f="16103" txt_i="8677" txt_f="8689">As shown in </offsets><xref ref-type="fig" rid="f1-medscimonit-19-751"><offsets xml_i="16152" xml_f="16160" txt_i="8689" txt_f="8697">Figure 1</offsets></xref><offsets xml_i="16167" xml_f="16615" txt_i="8697" txt_f="9145">, HBV DNA levels decreased in the LAM + ADV group from 3.18±0.73 to 2.82±0.38, 2.72±0.09, and 2.70±0.00 at weeks 12, 24, 52, and 104, respectively, of treatment. In the ETV group, HBV DNA levels decreased from 3.15±0.72 to 2.73±0.10, 2.75±0.21, 2.70±0.00 at weeks 12, 24, 52, and 104, respectively. There was no statistically significant difference between the 2 groups (P=0.879, 0.272, 0.592, and 1.000 at weeks 12, 24, 52, and 104, respectively).</offsets></p><p><offsets xml_i="16622" xml_f="16964" txt_i="9146" txt_f="9488">One patient quit ETV+ADV therapy because of poor efficacy (the HBV-DNA of this patient could still be detected) in the LAM + ADV group in week 52. No HBV resistant mutations were found in this patient. The compliance of the patients was good. Therefore, it is possible that the poor drug response in some patients was due to drug resistance [</offsets><xref ref-type="bibr" rid="b13-medscimonit-19-751"><offsets xml_i="17015" xml_f="17017" txt_i="9488" txt_f="9490">13</offsets></xref><offsets xml_i="17024" xml_f="17213" txt_i="9490" txt_f="9679">] that could not be detected. Another patient stopped taking the medicine on his own. This patient’s HBV had no detectable resistance genes. Both cases were considered to be non-responders.</offsets></p></sec><sec><title><offsets xml_i="17235" xml_f="17249" txt_i="9681" txt_f="9695">HBeAg response</offsets></title><p><offsets xml_i="17260" xml_f="17276" txt_i="9696" txt_f="9712">As described in </offsets><xref ref-type="fig" rid="f2-medscimonit-19-751"><offsets xml_i="17325" xml_f="17333" txt_i="9712" txt_f="9720">Figure 2</offsets></xref><offsets xml_i="17340" xml_f="17774" txt_i="9720" txt_f="10154">, HBeAg levels in the LAM + ADV group were 1.81±1.01, 1.52±0.86, 1.26±0.93, and 0.71±0.93 at weeks 12, 24, 52, and 104 of treatment, respectively. In the ETV group, the levels of HBeAg were 1.66±0.99, 1.43±0.92, 1.12±0.91, and 0.69±0.83 at weeks 12, 24, 52, and 104, respectively. There were no statistically significant differences between these 2 groups (P=0.668, 0.729, 0.614, and 0.955 at weeks 12, 24, 52, and 104, respectively).</offsets></p><p><offsets xml_i="17781" xml_f="18251" txt_i="10155" txt_f="10625">Of the 25 patients in the LAM + ADV group, 8% (2/25), 8% (2/25), 12% (3/25), and 32% (8/25) achieved HBeAg negative status by weeks 12, 24, 52, and 104, respectively. Of the other 25 patients in the ETV group, 4% (1/25), 8% (2/25), 16% (4/25), and 24% (6/25) of patients had undetectable HBV DNA by weeks 12, 24, 52, and 104, respectively. There were no statistically significant differences between the HBeAg seroconversion rates between the 2 groups at various times (</offsets><xref ref-type="fig" rid="f3-medscimonit-19-751"><offsets xml_i="18300" xml_f="18308" txt_i="10625" txt_f="10633">Figure 3</offsets></xref><offsets xml_i="18315" xml_f="18317" txt_i="10633" txt_f="10635">).</offsets></p><p><offsets xml_i="18324" xml_f="18797" txt_i="10636" txt_f="11109">Of the 25 patients in the LAM + ADV group, 8% (2/25), 8% (2/25), 12% (3/25), and 28% (7/25) of patients achieved HBeAg seroconversion by weeks 12, 24, 52, and 104, respectively. Of the other 25 patients in the ETV group, 4% (1/25), 8% (2/25), 12% (3/25), and 20% (5/25) of patients had HBeAg seroconversion by weeks 12, 24, 52 and 104, respectively. There were no statistically significant differences in HBeAg seroconversion rates between these 2 groups at various times (</offsets><xref ref-type="fig" rid="f4-medscimonit-19-751"><offsets xml_i="18846" xml_f="18854" txt_i="11109" txt_f="11117">Figure 4</offsets></xref><offsets xml_i="18861" xml_f="18863" txt_i="11117" txt_f="11119">).</offsets></p></sec><sec><title><offsets xml_i="18885" xml_f="18905" txt_i="11121" txt_f="11141">Biochemical response</offsets></title><p><offsets xml_i="18916" xml_f="19377" txt_i="11142" txt_f="11603">Of the 25 patients receiving LAM + ADV, 71% (17/24), 83% (20/24), 88% (22/25), and 88% (22/25) of patient had ALT normalization by weeks 12, 24, 52, and 104, respectively. Of the 25 patients receiving ETV, 60% (15/25), 79% (19/24), 80% (20/25), and 84% (21/25) of patients had ALT normalization by weeks 12, 24, 52, and 104, respectively. There were no statistically significant differences in the ALT normalization rates between the 2 groups at various times (</offsets><xref ref-type="fig" rid="f5-medscimonit-19-751"><offsets xml_i="19426" xml_f="19434" txt_i="11603" txt_f="11611">Figure 5</offsets></xref><offsets xml_i="19441" xml_f="19443" txt_i="11611" txt_f="11613">).</offsets></p></sec><sec><title><offsets xml_i="19465" xml_f="19480" txt_i="11615" txt_f="11630">Adverse effects</offsets></title><p><offsets xml_i="19491" xml_f="20030" txt_i="11631" txt_f="12170">Both monotherapy and combination therapy were well tolerated. No patient in either group discontinued the drug during the period except the 2 cases considered to be non-responders. Adverse effects in the ETV group were noted in only 1 patient by week 12 who had a serum total bilirubin level that was slightly increased to 33.3 mmol/L. This was monitored closely, but did not require any additional treatment. The total bilirubin of this patient normalized by week 24 and remained within normal limits for the duration of the study period.</offsets></p></sec><sec><title><offsets xml_i="20052" xml_f="20096" txt_i="12172" txt_f="12216">Virological breakthrough and drug resistance</offsets></title><p><offsets xml_i="20107" xml_f="20352" txt_i="12217" txt_f="12462">During the 104-week treatment period, virological breakthrough did not occur in any of the 50 patients included in this study. However, the 2 groups each had 1 case of non-response to treatment. No LAM- or ADV-associated mutations were detected.</offsets></p></sec></sec><sec sec-type="discussion"><title><offsets xml_i="20402" xml_f="20412" txt_i="12465" txt_f="12475">Discussion</offsets></title><p><offsets xml_i="20423" xml_f="20834" txt_i="12476" txt_f="12887">Management of CHB has improved greatly with the development of orally available nucleosides. Unfortunately, there are no agents available with sufficient efficacy and safety to fully eradicate HBV. In addition, long-term therapy is often associated with the development of antiviral drug resistance. Drug resistance is one of the most important factors limiting long-term nucleoside treatment for CHB patients [</offsets><xref ref-type="bibr" rid="b14-medscimonit-19-751"><offsets xml_i="20885" xml_f="20887" txt_i="12887" txt_f="12889">14</offsets></xref><offsets xml_i="20894" xml_f="21167" txt_i="12889" txt_f="13162">]. Based on the paradigm that a drug combination is more effective than monotherapy for the treatment of human immunodeficiency virus (HIV), the same approach may be appropriate for chronic hepatitis B. Few studies have assessed combination therapy in chronic hepatitis B [</offsets><xref ref-type="bibr" rid="b12-medscimonit-19-751"><offsets xml_i="21218" xml_f="21220" txt_i="13162" txt_f="13164">12</offsets></xref><offsets xml_i="21227" xml_f="21228" txt_i="13164" txt_f="13165">,</offsets><xref ref-type="bibr" rid="b15-medscimonit-19-751"><offsets xml_i="21279" xml_f="21281" txt_i="13165" txt_f="13167">15</offsets></xref><offsets xml_i="21288" xml_f="21289" txt_i="13167" txt_f="13168">,</offsets><xref ref-type="bibr" rid="b16-medscimonit-19-751"><offsets xml_i="21340" xml_f="21342" txt_i="13168" txt_f="13170">16</offsets></xref><offsets xml_i="21349" xml_f="21390" txt_i="13170" txt_f="13211">]. From those studies, it was shown that </offsets><italic><offsets xml_i="21398" xml_f="21405" txt_i="13211" txt_f="13218">de novo</offsets></italic><offsets xml_i="21414" xml_f="21574" txt_i="13218" txt_f="13378"> combination therapy with LAM and ADV was better than add-on combination therapy in terms of changes in Child-Pugh score, viral inhibition, and renal function [</offsets><xref ref-type="bibr" rid="b15-medscimonit-19-751"><offsets xml_i="21625" xml_f="21627" txt_i="13378" txt_f="13380">15</offsets></xref><offsets xml_i="21634" xml_f="21781" txt_i="13380" txt_f="13527">]. Patients treated with LAM plus ADV exhibited significantly greater virological, biochemical, and serological responses compared with LAM alone [</offsets><xref ref-type="bibr" rid="b16-medscimonit-19-751"><offsets xml_i="21832" xml_f="21834" txt_i="13527" txt_f="13529">16</offsets></xref><offsets xml_i="21841" xml_f="21876" txt_i="13529" txt_f="13564">], but not compared with entecavir.</offsets></p><p><offsets xml_i="21883" xml_f="22026" txt_i="13565" txt_f="13708">Lamivudine is an inexpensive agent, with few adverse effects. However, there are very high rates of resistance with long-term LAM monotherapy [</offsets><xref ref-type="bibr" rid="b17-medscimonit-19-751"><offsets xml_i="22077" xml_f="22079" txt_i="13708" txt_f="13710">17</offsets></xref><offsets xml_i="22086" xml_f="22087" txt_i="13710" txt_f="13711">–</offsets><xref ref-type="bibr" rid="b20-medscimonit-19-751"><offsets xml_i="22138" xml_f="22140" txt_i="13711" txt_f="13713">20</offsets></xref><offsets xml_i="22147" xml_f="22316" txt_i="13713" txt_f="13882">]. Adefovir is a nucleotide analog that has been shown to be effective against LAM-resistant HBV. Entecavir is a potent HBV inhibitor with a high barrier to resistance [</offsets><xref ref-type="bibr" rid="b21-medscimonit-19-751"><offsets xml_i="22367" xml_f="22369" txt_i="13882" txt_f="13884">21</offsets></xref><offsets xml_i="22376" xml_f="22377" txt_i="13884" txt_f="13885">–</offsets><xref ref-type="bibr" rid="b26-medscimonit-19-751"><offsets xml_i="22428" xml_f="22430" txt_i="13885" txt_f="13887">26</offsets></xref><offsets xml_i="22437" xml_f="22656" txt_i="13887" txt_f="14106">]. According to the 2012 EASL guidelines, entecavir can be confidently used as first-line monotherapy. However, which agents should be combined, duration of therapy, and when to change or stop treatment remain unclear [</offsets><xref ref-type="bibr" rid="b27-medscimonit-19-751"><offsets xml_i="22707" xml_f="22709" txt_i="14106" txt_f="14108">27</offsets></xref><offsets xml_i="22716" xml_f="22718" txt_i="14108" txt_f="14110">].</offsets></p><p><offsets xml_i="22725" xml_f="23727" txt_i="14111" txt_f="15113">An important question is whether combination therapy is necessary according to the conclusion from the current study. Initial combination therapy or use of agents with a high genetic barrier is recommended in patients with a high risk of developing drug resistance and potentially life-threatening disease (e.g., cirrhosis). Based on this principle, the best option for naïve CHB patients who are HBeAg-positive or have serious liver disease, such as cirrhosis, is either combination treatment or monotherapy with high genetic barrier drugs to reduce the occurrence of HBV resistance. In our study, more patients in the combination treatment group achieved HBeAg seroconversion than in the monotherapy group, although the differences in HBeAg seroconversion rates between the 2 groups were not statistically significant. Many factors have been found to be associated with HBeAg seroconversion, including decreased titers of HBeAg in the serum and increased grades of lobular inflammation in the liver [</offsets><xref ref-type="bibr" rid="b28-medscimonit-19-751"><offsets xml_i="23778" xml_f="23780" txt_i="15113" txt_f="15115">28</offsets></xref><offsets xml_i="23787" xml_f="23798" txt_i="15115" txt_f="15126">]. Whether </offsets><italic><offsets xml_i="23806" xml_f="23813" txt_i="15126" txt_f="15133">de novo</offsets></italic><offsets xml_i="23822" xml_f="23929" txt_i="15133" txt_f="15240"> combination therapy with LAM and ADV could affect HBeAg seroconversion long-term remains to be determined.</offsets></p><p><offsets xml_i="23936" xml_f="24162" txt_i="15241" txt_f="15467">In the patients with severe acute exacerbation of chronic hepatitis B, entecavir monotherapy treatment may achieve better virological response in the long run, but this has been associated with increased short-term mortality [</offsets><xref ref-type="bibr" rid="b29-medscimonit-19-751"><offsets xml_i="24213" xml_f="24215" txt_i="15467" txt_f="15469">29</offsets></xref><offsets xml_i="24222" xml_f="24334" txt_i="15469" txt_f="15581">]. Entecavir monotherapy did not reduce the incidence of hepatic carcinoma in patients with cirrhosis in Japan [</offsets><xref ref-type="bibr" rid="b30-medscimonit-19-751"><offsets xml_i="24385" xml_f="24387" txt_i="15581" txt_f="15583">30</offsets></xref><offsets xml_i="24394" xml_f="24426" txt_i="15583" txt_f="15615">]. Based on these observations, </offsets><italic><offsets xml_i="24434" xml_f="24441" txt_i="15615" txt_f="15622">de novo</offsets></italic><offsets xml_i="24450" xml_f="24579" txt_i="15622" txt_f="15751"> combination of lamivudine and adefovir may be a better choice than entecavir monotherapy, especially in severe CHB or cirrhosis.</offsets></p><p><offsets xml_i="24586" xml_f="24716" txt_i="15752" txt_f="15882">There are several shortcomings in the present study. The number of subjects was small because the number of patients treated with </offsets><italic><offsets xml_i="24724" xml_f="24731" txt_i="15882" txt_f="15889">de novo</offsets></italic><offsets xml_i="24740" xml_f="24991" txt_i="15889" txt_f="16140"> combination therapy is limited in China. The limit of detection of HBV-DNA was 500 copies/ml, which was not as low as that used in several other studies, and which might account for differences observed in the current study compared to previous ones.</offsets></p></sec><sec sec-type="conclusions"><title><offsets xml_i="25036" xml_f="25047" txt_i="16142" txt_f="16153">Conclusions</offsets></title><p><offsets xml_i="25058" xml_f="25432" txt_i="16154" txt_f="16528">In conclusion, the current study shows that there was no statistical significance between the 2 groups in terms of rates of HBV DNA negativity, HBeAg negativity, HBeAg seroconversion, and ALT biochemical response. These findings indicate that the combination of LAM plus ADV is as good as entecavir monotherapy for the treatment of naïve CHB patients who are HBeAg-positive.</offsets></p></sec></body><back><ack><title>Acknowledgments</title><p>We thank Medjaden Bioscience Limited for assisting in the preparation of this manuscript.</p></ack><fn-group><fn id="fn8-medscimonit-19-751"><p><bold>Source of support:</bold> Departmental sources</p></fn></fn-group><ref-list><title>References</title><ref id="b1-medscimonit-19-751"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fallot</surname><given-names>G</given-names></name><name><surname>Neuveut</surname><given-names>C</given-names></name><name><surname>Buendia</surname><given-names>MA</given-names></name></person-group><article-title>Diverse roles of hepatitis B virus in liver cancer</article-title><source>Curr Opin Virol</source><year>2012</year><volume>2</volume><issue>4</issue><fpage>467</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">22722078</pub-id></element-citation></ref><ref id="b2-medscimonit-19-751"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>CF</given-names></name><name><surname>Lee</surname><given-names>WC</given-names></name><name><surname>Yang</surname><given-names>HI</given-names></name><etal></etal></person-group><article-title>Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma</article-title><source>Gastroenterology</source><year>2011</year><volume>141</volume><issue>4</issue><fpage>1240</fpage><lpage>48</lpage><comment>;1248.et-2</comment><pub-id pub-id-type="pmid">21703214</pub-id></element-citation></ref><ref id="b3-medscimonit-19-751"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santantonio</surname><given-names>T</given-names></name><name><surname>Mazzola</surname><given-names>M</given-names></name><name><surname>Pastore</surname><given-names>G</given-names></name></person-group><article-title>Lamivudine is safe and effective in fulminant hepatitis B</article-title><source>J Hepatol</source><year>1999</year><volume>30</volume><issue>3</issue><fpage>551</fpage><pub-id pub-id-type="pmid">10190743</pub-id></element-citation></ref><ref id="b4-medscimonit-19-751"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perrillo</surname><given-names>R</given-names></name><name><surname>Hann</surname><given-names>HW</given-names></name><name><surname>Mutimer</surname><given-names>D</given-names></name><etal></etal></person-group><article-title>Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus</article-title><source>Gastroenterology</source><year>2004</year><volume>126</volume><fpage>81</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">14699490</pub-id></element-citation></ref><ref id="b5-medscimonit-19-751"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peters</surname><given-names>MG</given-names></name><name><surname>Hann</surname><given-names>HwH</given-names></name><name><surname>Martin</surname><given-names>P</given-names></name><etal></etal></person-group><article-title>Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B</article-title><source>Gastroenterology</source><year>2004</year><volume>126</volume><fpage>91</fpage><lpage>101</lpage><pub-id pub-id-type="pmid">14699491</pub-id></element-citation></ref><ref id="b6-medscimonit-19-751"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>HJ</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>YJ</given-names></name><etal></etal></person-group><article-title>Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance</article-title><source>J Med Virol</source><year>2012</year><volume>84</volume><issue>3</issue><fpage>424</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">22246827</pub-id></element-citation></ref><ref id="b7-medscimonit-19-751"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buti</surname><given-names>M</given-names></name><name><surname>Morillas</surname><given-names>RM</given-names></name><name><surname>Prieto</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Efficacy and safety of entecavir in clinical practice in treatment-naive Caucasian chronic hepatitis B patients</article-title><source>Eur J Gastroenterol Hepatol</source><year>2012</year><volume>24</volume><issue>5</issue><fpage>535</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">22382708</pub-id></element-citation></ref><ref id="b8-medscimonit-19-751"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Degertekin</surname><given-names>B</given-names></name><name><surname>Lok</surname><given-names>AS</given-names></name></person-group><article-title>Update on viral hepatitis: 2008</article-title><source>Curr Opin Gastroenterol</source><year>2009</year><volume>25</volume><fpage>180</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">19387254</pub-id></element-citation></ref><ref id="b9-medscimonit-19-751"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akuta</surname><given-names>N</given-names></name><name><surname>Suzuki</surname><given-names>F</given-names></name><name><surname>Kawamura</surname><given-names>Y</given-names></name><etal></etal></person-group><article-title>Virological response and hepatocarcinogenesis in lamivudine-resistant hepatitis B virus genotype C patients treated with lamivudine plus adefovir dipivoxil</article-title><source>Intervirology</source><year>2008</year><volume>51</volume><fpage>385</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">19229115</pub-id></element-citation></ref><ref id="b10-medscimonit-19-751"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>EQ</given-names></name><name><surname>Wang</surname><given-names>LC</given-names></name><name><surname>Lei</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Meta-analysis: Adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus</article-title><source>Virol J</source><year>2009</year><volume>6</volume><fpage>163</fpage><pub-id pub-id-type="pmid">19818142</pub-id></element-citation></ref><ref id="b11-medscimonit-19-751"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ijaz</surname><given-names>S</given-names></name><name><surname>Arnold</surname><given-names>C</given-names></name><name><surname>Dervisevic</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Dynamics of lamivudineresistant hepatitis B virus during adefovir monotherapy <italic>versus</italic> lamivudine plus adefovir combination therapy</article-title><source>J Med Virol</source><year>2008</year><volume>80</volume><fpage>1160</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">18461609</pub-id></element-citation></ref><ref id="b12-medscimonit-19-751"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>LC</given-names></name><name><surname>Chen</surname><given-names>EQ</given-names></name><name><surname>Cao</surname><given-names>J</given-names></name><etal></etal></person-group><article-title><italic>De novo</italic> combination of lamivudine and adefovir <italic>versus</italic> entecavir monotherapy for the treatment of naïve HBeAg-negative chronic hepatitis B patients</article-title><source>Hepatol Int</source><year>2011</year><volume>5</volume><fpage>671</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">21484140</pub-id></element-citation></ref><ref id="b13-medscimonit-19-751"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>LH</given-names></name><name><surname>Liu</surname><given-names>CM</given-names></name><etal></etal></person-group><article-title>Characterization of hepatitis B virus reverse transcriptase sequences in Chinese tratment naive patients</article-title><source>J Gastroenrol Hepatol</source><year>2009</year><volume>24</volume><fpage>1417</fpage><lpage>23</lpage></element-citation></ref><ref id="b14-medscimonit-19-751"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papatheodoridis</surname><given-names>GV</given-names></name><name><surname>Deutsch</surname><given-names>M</given-names></name></person-group><article-title>Resistance issues in treating chronic hepatitis B</article-title><source>Future Microbiol</source><year>2008</year><volume>3</volume><fpage>525</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">18811237</pub-id></element-citation></ref><ref id="b15-medscimonit-19-751"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>XH</given-names></name><name><surname>Geng</surname><given-names>JZ</given-names></name><name><surname>Wang</surname><given-names>LF</given-names></name><etal></etal></person-group><article-title><italic>De novo</italic> combination therapy with lamivudine and adefovir dipivoxil in chronic hepatitis B patients</article-title><source>World J Gastroenterol</source><year>2011</year><volume>17</volume><issue>43</issue><fpage>4804</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">22147982</pub-id></element-citation></ref><ref id="b16-medscimonit-19-751"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Wu</surname><given-names>XL</given-names></name><name><surname>Zeng</surname><given-names>WZ</given-names></name><etal></etal></person-group><article-title>Lamivudine plus adefovir is a good option for chronic hepatitis B patients with viral relapse after cessation of lamivudine treatment</article-title><source>Virol J</source><year>2011</year><volume>8</volume><fpage>388</fpage><pub-id pub-id-type="pmid">21816062</pub-id></element-citation></ref><ref id="b17-medscimonit-19-751"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lok</surname><given-names>AS</given-names></name><name><surname>Hussain</surname><given-names>M</given-names></name><name><surname>Cursano</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>Evolution of hepatitis B virus polymerase gene mutations in hepatitis B eantigen-negative patients receiving lamivudine therapy</article-title><source>Hepatology</source><year>2000</year><volume>32</volume><fpage>1145</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">11050068</pub-id></element-citation></ref><ref id="b18-medscimonit-19-751"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hadziyannis</surname><given-names>SJ</given-names></name><name><surname>Papatheodoridis</surname><given-names>GV</given-names></name><name><surname>Dimou</surname><given-names>E</given-names></name><etal></etal></person-group><article-title>Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B</article-title><source>Hepatology</source><year>2000</year><volume>32</volume><fpage>847</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">11003633</pub-id></element-citation></ref><ref id="b19-medscimonit-19-751"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papatheodoridis</surname><given-names>GV</given-names></name><name><surname>Dimou</surname><given-names>E</given-names></name><name><surname>Laras</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease</article-title><source>Hepatology</source><year>2000</year><volume>36</volume><fpage>219</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">12085368</pub-id></element-citation></ref><ref id="b20-medscimonit-19-751"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Marco</surname><given-names>V</given-names></name><name><surname>Marzano</surname><given-names>A</given-names></name><name><surname>Lampertico</surname><given-names>P</given-names></name><etal></etal></person-group><article-title>Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine</article-title><source>Hepatology</source><year>2004</year><volume>40</volume><fpage>883</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">15382125</pub-id></element-citation></ref><ref id="b21-medscimonit-19-751"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>TT</given-names></name><name><surname>Gish</surname><given-names>RG</given-names></name><name><surname>de Man</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B</article-title><source>N Engl J Med</source><year>2006</year><volume>354</volume><fpage>1001</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">16525137</pub-id></element-citation></ref><ref id="b22-medscimonit-19-751"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcellin</surname><given-names>P</given-names></name><name><surname>Heathcote</surname><given-names>EJ</given-names></name><name><surname>Buti</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Tenofovir disoproxil fumarate <italic>versus</italic> adefovir dipivoxil for chronic hepatitis B</article-title><source>N Engl J Med</source><year>2008</year><volume>359</volume><fpage>2442</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">19052126</pub-id></element-citation></ref><ref id="b23-medscimonit-19-751"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcellin</surname><given-names>P</given-names></name><name><surname>Chang</surname><given-names>TT</given-names></name><name><surname>Lim</surname><given-names>SG</given-names></name><etal></etal></person-group><article-title>Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B</article-title><source>Hepatology</source><year>2008</year><volume>48</volume><fpage>750</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">18752330</pub-id></element-citation></ref><ref id="b24-medscimonit-19-751"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heathcote</surname><given-names>EJ</given-names></name><name><surname>Marcellin</surname><given-names>P</given-names></name><name><surname>Buti</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B</article-title><source>Gastroenterology</source><year>2011</year><volume>140</volume><fpage>132</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">20955704</pub-id></element-citation></ref><ref id="b25-medscimonit-19-751"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>CL</given-names></name><name><surname>Shouval</surname><given-names>D</given-names></name><name><surname>Lok</surname><given-names>AS</given-names></name><etal></etal></person-group><article-title>Entecavir <italic>versus</italic> lamivudine for patients with HBeAg-negative chronic hepatitis B</article-title><source>N Engl J Med</source><year>2006</year><volume>354</volume><fpage>1011</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">16525138</pub-id></element-citation></ref><ref id="b26-medscimonit-19-751"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcellin</surname><given-names>P</given-names></name><name><surname>Heathcote</surname><given-names>EJ</given-names></name><name><surname>Corsa</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>No detectable resistance to tenofovir disoproxil fumarate (TDF) following up to 240 weeks of treatment in patients with HBeAg+ and HbeAg– chronic hepatitis B virus infection</article-title><source>Hepatology</source><year>2011</year><volume>54</volume><fpage>480A</fpage></element-citation></ref><ref id="b27-medscimonit-19-751"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morgan</surname><given-names>M</given-names></name><name><surname>Keeffe</surname><given-names>EB</given-names></name></person-group><article-title>Diagnosis and treatment of chronic hepatitis B: 2009 update</article-title><source>Minerva Gastroenterol Dietol</source><year>2009</year><volume>55</volume><issue>1</issue><fpage>5</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">19212304</pub-id></element-citation></ref><ref id="b28-medscimonit-19-751"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bae</surname><given-names>SK</given-names></name><name><surname>Yatsuhashi</surname><given-names>H</given-names></name><name><surname>Hashimoto</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Prediction of early HBeAg seroconversion by decreased titers of HBeAg in the serum combined with increased grades of lobular inflammation in the liver</article-title><source>Med Sci Monit</source><year>2012</year><volume>18</volume><issue>12</issue><fpage>CR698</fpage><lpage>705</lpage><pub-id pub-id-type="pmid">23197230</pub-id></element-citation></ref><ref id="b29-medscimonit-19-751"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>VW</given-names></name><name><surname>Wong</surname><given-names>GL</given-names></name><name><surname>Yiu</surname><given-names>KK</given-names></name><etal></etal></person-group><article-title>Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B</article-title><source>J Hepatol</source><year>2011</year><volume>54</volume><fpage>236</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">21030105</pub-id></element-citation></ref><ref id="b30-medscimonit-19-751"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobashi</surname><given-names>H</given-names></name><name><surname>Miyake</surname><given-names>Y</given-names></name><name><surname>lkeda</surname><given-names>F</given-names></name><etal></etal></person-group><article-title>Long-term outcome and hepatocellular carcinoma development in chronic hepatitis B or cirrhosis patients after nucleoside analog treatment with entecavir or lamivudine</article-title><source>Hepato Res</source><year>2011</year><volume>41</volume><fpage>405</fpage><lpage>16</lpage></element-citation></ref></ref-list></back><floats-group><fig id="f1-medscimonit-19-751" position="float"><label>Figure 1</label><caption><p>The decreasing trend of HBV DNA over time.</p></caption><graphic xlink:href="medscimonit-19-751-g001"></graphic></fig><fig id="f2-medscimonit-19-751" position="float"><label>Figure 2</label><caption><p>The decreasing trend of HBeAg with time.</p></caption><graphic xlink:href="medscimonit-19-751-g002"></graphic></fig><fig id="f3-medscimonit-19-751" position="float"><label>Figure 3</label><caption><p>HBeAg-negativity rate of the 2 groups in different times.</p></caption><graphic xlink:href="medscimonit-19-751-g003"></graphic></fig><fig id="f4-medscimonit-19-751" position="float"><label>Figure 4</label><caption><p>HBeAg seroconversion rates between the 2 groups at various times.</p></caption><graphic xlink:href="medscimonit-19-751-g004"></graphic></fig><fig id="f5-medscimonit-19-751" position="float"><label>Figure 5</label><caption><p>ALT biochemical response rates of the 2 groups at various times.</p></caption><graphic xlink:href="medscimonit-19-751-g005"></graphic></fig><table-wrap id="t1-medscimonit-19-751" position="float"><label>Table 1</label><caption><p>Characteristics of patients at baseline.</p></caption><table frame="hsides" rules="rows"><thead><tr><th align="center" valign="bottom" rowspan="1" colspan="1">Characteristic</th><th align="center" valign="bottom" rowspan="1" colspan="1">LAM + ADV</th><th align="center" valign="bottom" rowspan="1" colspan="1">ETV</th><th align="center" valign="bottom" rowspan="1" colspan="1">P value</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Patients enrolled</td><td align="center" valign="top" rowspan="1" colspan="1">25</td><td align="center" valign="top" rowspan="1" colspan="1">25</td><td align="left" valign="top" rowspan="1" colspan="1"></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age (yrs)</td><td align="center" valign="top" rowspan="1" colspan="1">33.4±9.8</td><td align="center" valign="top" rowspan="1" colspan="1">30.8±7.1</td><td align="left" valign="top" rowspan="1" colspan="1">0.28</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Gender (males %)</td><td align="center" valign="top" rowspan="1" colspan="1">20 (80%)</td><td align="center" valign="top" rowspan="1" colspan="1">19 (76%)</td><td align="left" valign="top" rowspan="1" colspan="1">0.21</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HBeAg (S/CO)</td><td align="center" valign="top" rowspan="1" colspan="1">2.64±0.64</td><td align="center" valign="top" rowspan="1" colspan="1">2.44±0.79</td><td align="left" valign="top" rowspan="1" colspan="1">0.35</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HBV DNA (copies/ml)</td><td align="center" valign="top" rowspan="1" colspan="1">6.02±1.62</td><td align="center" valign="top" rowspan="1" colspan="1">5.94±1.25</td><td align="left" valign="top" rowspan="1" colspan="1">0.837</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ALT (IU/L)</td><td align="center" valign="top" rowspan="1" colspan="1">Median=173</td><td align="center" valign="top" rowspan="1" colspan="1">Median=156</td><td align="left" valign="top" rowspan="1" colspan="1">0.83</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AST (IU/L)</td><td align="center" valign="top" rowspan="1" colspan="1">Median=92</td><td align="center" valign="top" rowspan="1" colspan="1">Median=77</td><td align="left" valign="top" rowspan="1" colspan="1">0.71</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TBil (μmol/L)</td><td align="center" valign="top" rowspan="1" colspan="1">21.14±17.06</td><td align="center" valign="top" rowspan="1" colspan="1">13.82±3.55</td><td align="left" valign="top" rowspan="1" colspan="1">0.14</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cr (μmol/L)</td><td align="center" valign="top" rowspan="1" colspan="1">59.12±11.30</td><td align="center" valign="top" rowspan="1" colspan="1">59.55±13.02</td><td align="left" valign="top" rowspan="1" colspan="1">0.90</td></tr></tbody></table></table-wrap></floats-group></article>